Status:
UNKNOWN
Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain
Lead Sponsor:
Mitos Pharmaceuticals
Conditions:
Alopecia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Hair loss occurs commonly as a result of radiotherapy administered to the brain, and this can contribute to the distress and social isolation of patients with advanced cancer. In this study a topical ...
Eligibility Criteria
Inclusion
- Metastatic cancer to the brain for which palliative whole brain radiotherapy is recommended.
- Hair that covers the scalp and is at least 1/4 inch in length
Exclusion
- Receiving chemotherapy known to cause alopecia within 60 days of study or during the study.
- Pre-existing alopecia
- Previous brain radiotherapy
- scalp metastases or scalp wounds
- use of hair dyes
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2010
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00801086
Start Date
November 1 2008
End Date
June 1 2010
Last Update
December 3 2008
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arizona
Tucson, Arizona, United States, 85724
2
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104